Polycystic ovary syndrome in pubertal period: Clinical, biological, metabolic and genetic polymorphism;Le syndrome des ovaires polykystiques en période péri-pubertaire: Polymorphisme clinique, biologique, métabolique et génétique

Gynecologie Obstetrique et Fertilite

Volumn 32, Issue 1, 2004, Pages 3-17

  Trimeche S ^a,b   Thuan Dit Dieudonne, J F ^a,b   Jeandel, C ^a   Paris, F ^a,b   Simoni Brum, I ^a   Orio, F ^a   Sultan, C ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

Adolescent; Hyperandrogenism; Polycystic ovary syndrome; Puberty

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CALPAIN; CYPROTERONE ACETATE; CYTOCHROME P450 17; FOLLISTATIN; FOLLITROPIN; FOLLITROPIN RECEPTOR; GLUCOCORTICOID; INSULIN; INSULIN RECEPTOR; RESISTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADOLESCENT; CLINICAL FEATURE; DISEASE CLASSIFICATION; ECHOGRAPHY; FAMILIAL DISEASE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPERANDROGENISM; MAJOR HISTOCOMPATIBILITY COMPLEX; MENARCHE; MOLECULAR DYNAMICS; OVARY POLYCYSTIC DISEASE; PUBERTY; REGULATORY MECHANISM; REVIEW; STEROIDOGENESIS;

EID: 0842281701     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2003.10.027     Document Type: Short Survey

References (113)

1. Sultan C., Missova S., Lumbroso S. Conduite à tenir devant une hyperandrogénie de l'adolescente. La revue Française d'Endocrinologie clinique nutrition et métabolisme. (4-5):1995;485-499.
2. Sultan C., Paris F., Jeandel C., Farret A., Attal G., Alirezai S., et al. Particularités du syndrome des ovaires polykystiques à la puberté Mise au point clinique d'endocrinologie, nutrition et métabolisme. 2001;105-114.
3. Avvad C.K., Holeuwerger R., Silva V.C., Bordallo M.A., Breitenbach M.M. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol. 15:(3):2001 Jun;170-177.
4. Urbanek M., Legro R.S., Driscoll D.A., Azziz R., Ehrmann D.A., Norman R.J., et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA. 96:(15):1999 Jul 20;8573-8578.
5. Franks S. Polycystic ovary syndrome. N Engl J Med. 333:(13):1995 Sep 28;853-861. Review.
6. Stein I.F., Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 29:1935;181-191.
7. Farquhar C.M., Birdsall M., Manning P., Mitchell J.M., France J.T. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol. 34:(1):1994 Feb;67-72.
8. Lee P.A., Siegel S.W. Androgens in infancy, childhood and adolescence. Redmond G.P. « Androgenic disorders » 1995;59-76 Raven Press.
9. Sample W.F., Lippe B.M., Gyepes M.T. Gray-scale ultrasonography of the normal female pelvis. Radiology. 125:(2):1977 Nov;477-483.
10. Ivarsson S.A., Nilsson K.O., Persson P.H. Ultrasonography of the pelvic organs in prepubertal and postpubertal girls. Arch Dis Child. 58:(5):1983 May;352-354.
11. Giorlandino C., Gleicher N., Taramanni C., Vizzone A., Gentili P., Mancuso S., et al. Ovarian development of the female child and adolescent: I. Morphology. Int J Gynaecol Obstet. 29:(1):1989 May;57-63.
12. Van Hooff M.H., Voorhorst F.J., Kaptein M.B., Hirasing R.A., Koppenaal C., Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril. 74:(1):2000 Jul;49-58.
13. Saenger P., Reiter E.O. Premature adrenarche: a normal variant of puberty? J Clin Endocrinol Metab. 74:(2):1992 Feb;236-238.
14. Korth-Schutz S., Levine L.S., New M.I. Evidence for the adrenal source of androgens in precocious adrenarche. Acta Endocrinol (Copenh). 82:(2):1976 Jun;342-352.
15. Rosenfield R.L. Plasma 17-ketosteroids and 17-beta hydroxysteroids in girls with premature development of sexual hair. J Pediatr. 79:1971;260-266.
16. Oberfield S.E., Mayes D.M., Levine L.S. Adrenal steroidogenic function in a black and Hispanic population with precocious pubarche. J Clin Endocrinol Metab. 70:(1):1990 Jan;76-82.
17. Ibanez L., Potau N., Virdis R., Zampolli M., Terzi C., Gussinye M., et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 76:(6):1993 Jun;1599-1603.
18. Battaglia C., Regnani G., Mancini F., Iughetti L., Bernasconi S., Volpe A., et al. Isolated premature pubarche: ultrasonographic and color Doppler analysis - a longitudinal study. J Clin Endocrinol Metab. 87:(7):2002 Jul;3148-3154.
19. Pugeat M., Cousin P., Baret C., Lejeune H., Forest M.G. Sex hormone-binding globulin during puberty in normal and hyperandrogenic girls. J Pediatr Endocrinol Metab. 13:(Suppl 5):2000;1277-1279.
20. De Bruin J.P., Nikkels P.G., Bruinse H.W., van Haaften M., Looman C.W., te Velde E.R. Morphometry of human ovaries in normal and growth-restricted fetuses. Early Hum Dev. 60:(3):2001 Jan;179-192.
21. Macklon N.S., Fauser B.C. Aspects of ovarian follicle development throughout life. Horm Res. 52:(4):1999;161-170.
22. Abbott D.H., Dumesic D.A., Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol. 174:(1):2002 Jul;1-5.
23. Ibanez L., Potau N., Zampolli M., Prat N., Virdis R., Vicens-Calvet E., et al. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 81:(3):1996 Mar;1237-1243.
24. Ibanez L., Potau N., Ferrer A., Rodriguez-Hierro F., Marcos M.V., de Zegher F. Reduced ovulation rate in adolescent girls born small for gestational age. J Clin Endocrinol Metab. 87:(7):2002 Jul;3391-3393.
25. Ibanez L., Potau N., Francois I., de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 83:(10):1998 Oct;3558-3562.
26. Ibanez L., Aulesa C., Potau N., Ong K., Dunger D.B., de Zegher F. Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatr Res. 51:(2):2002 Feb;244-248.
27. Apter D., Butzow T., Laughlin G.A., Yen S.S. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab. 79:(1):1994 Jul;119-125.
28. Lazar L., Kauli R., Bruchis C., Nordenberg J., Galatzer A., Pertzelan A. High prevalence of abnormal adrenal response in girls with central precocious puberty at early pubertal stages. Eur J Endocrinol. 133:(4):1995 Oct;407-411.
29. Veldhuis J.D., Pincus S.M., Garcia-Rudaz M.C., Ropelato M.G., Escobar M.E., Barontini M. Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab. 86:(1):2001 Jan;72-79.
30. Jay N., Mansfield M.J., Blizzard R.M., Crowley W.F. Jr, Schoenfeld D., Rhubin L., et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 75:(3):1992 Sep;890-894.
31. Bridges N.A., Cooke A., Healy M.J., Hindmarsh P.C., Brook C.G. Ovaries in sexual precocity. Clin Endocrinol (Oxf). 42:(2):1995 Feb;135-140.
32. Bloch C.A., Clemons P., Sperling M.A. Puberty decreases insulin sensitivity. J Pediatr. 110:(3):1987 Mar;481-487.
33. Amiel S.A., Caprio S., Sherwin R.S., Plewe G., Haymond M.W., Tamborlane W.V. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab. 72:(2):1991 Feb;277-282.
34. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:(9):1989 Sep;1165-1174.
35. Apter D., Butzow T., Laughlin G.A., Yen S.S. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 80:(10):1995 Oct;2966-2973.
36. Ibanez L., Potau N., Zampolli M., Rique S., Saenger P., Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab. 82:(7):1997 Jul;2283-2288.
37. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 83:(8):1998 Aug;2694-2698.
38. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:(7):1985 Jul;412-419.
39. Bergman R.N., Finegood D.T., Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 6:(1):1985 Winter;45-86.
40. Lewy V.D., Danadian K., Witchel S.F., Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 138:(1):2001 Jan;38-44.
41. Arslanian S.A., Lewy V.D., Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 86:(1):2001 Jan;66-71.
42. O'Meara N.M., Blackman J.D., Ehrmann D.A., Barnes R.B., Jaspan J.B., Rosenfield R.L., et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 76:(5):1993 May;1241-1247.
43. Holte J., Bergh T., Berne C., Berglund L., Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab. 78:(5):1994 May;1052-1058.
44. Jayagopal V., Kilpatrick E.S., Jennings P.E., Hepburn D.A., Atkin S.L. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab. 88:(4):2003 Apr;1528-1533.
45. Haffner S.M., Katz M.S., Stern M.P., Dunn J.F. Association of decreased sex hormone binding globulin and cardiovascular risk factors. Arteriosclerosis. 9:(1):1989 Jan-Feb;136-143.
46. Yildiz B.O., Yarali H., Oguz H., Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:(5):2003 May;2031-2036.
47. Lanzone A., Villa P., Fulghesu A.M., Pavone V., Caruso A., Mancuso S. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia. Hum Reprod. 10:(7):1995 Jul;1653-1657.
48. Villa P., Rossodivita A., Fulghesu A.M., Cucinelli F., Barini A., Apa R., et al. Insulin and GH secretion in adolescent girls with irregular cycles: polycystic vs multifollicular ovaries. J Endocrinol Invest. 26:(4):2003 Apr;305-311.
49. Villa P., Valle D., Mancini A., De Marinis L., Pavone V., Fulghesu A.M., Mancuso S., Lanzone A. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism. Fertil Steril. 71:(1):1999 Jan;115-121.
50. Ibanez L., Potau N., Zampolli M., Prat N., Gussinye M., Saenger P., et al. Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab. 79:(6):1994 Dec;1778-1784.
51. Terouanne B., Paris F., Servant N., Georget V., Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol. 198:(1-2):2002 Dec 30;143-147.
52. Kahsar-Miller M.D., Nixon C., Boots L.R., Go R.C., Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 75:(1):2001 Jan;53-58.
53. Cooper H.E., Spellacy W.N., Prem K.A., Cohen W.D. Herditary factors in Stein-Leventhal Syndrome. Am J Obstet Gynecol. 100:1968;371-382.
54. Carey A.H., Chan K.L., Short F., White D., Williamson R., Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf). 38:(6):1993 Jun;653-658.
55. Govind A., Obhrai M.S., Clayton R.N. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 84:(1):1999 Jan;38-43.
56. Givens J.R. Familial polycystic ovarian disease. Endocrinol Metab Clin North Am. 17:(4):1988 Dec;771-783. Review.
57. Jahanfar S., Eden J.A., Nguyen T., Wang X.L., Wilcken D.E. A twin study of polycystic ovary syndrome and lipids. Gynecol Endocrinol. 11:(2):1997 Apr;111-117.
58. Gharani N., Waterworth D.M., Batty S., White D., Gilling-Smith C., Conway G.S., et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet. 6:(3):1997 Mar;397-402.
59. Pugeat M., Cousin P., Nicolas M.H., et al. Pentanucleotide repeat polymorphism in the promotor region of the human CYP11A gene And polycystic ovaries in hirsute women. Proceedings of the endocrine society, 81st, Annual meeting. San Diego California:1999.
60. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:(9):1996 Aug 29;617-623.
61. Ehrmann D.A., Rosenfield R.L., Barnes R.B., Brigell D.F., Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 327:(3):1992 Jul 16;157-162.
62. Qin K.N., Rosenfield R.L. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol. 145:(1-2):1998 Oct 25;111-121. Review.
63. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 3:(10):1994 Oct;1873-1876.
64. Diamanti-Kandarakis E., Bartzis M.I., Zapanti E.D., Spina G.G., Filandra F.A., Tsianateli T.C., et al. Polymorphism T - >C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril. 71:(3):1999 Mar;431-435.
65. Gharani N., Waterworth D.M., Williamson R., Franks S. 5' polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab. 81:(11):1996 Nov;4174.
66. Wickenheisser J.K., Quinn P.G., Nelson V.L., Legro R.S., Strauss J.F. 3rd, McAllister J.M. Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab. 85:(6):2000 Jun;2304-2311.
67. Wood J.R., Nelson V.L., Ho C., Jansen E., Wang C.Y., Urbanek M., et al. The molecular phenotype of polycystic ovary syndrome (PCOS) Theca cells and newcandidate PCOS genes defined by microarray analysis. J Biol Chem. 2003 May 6.
68. Escobar-Morreale H.F., San Millan J.L., Smith R.R., Sancho J., Witchel S.F. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. Fertil Steril. 72:(4):1999 Oct;629-638.
69. Azziz R., Owerbach D. Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to short-term adrenal stimulation. Am J Obstet Gynecol. 172:(3):1995 Mar;914-918.
70. Witchel S.F., Lee P.A., Suda-Hartman M., Hoffman E.P. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med. 62:(2):1997 Dec;151-158.
71. Knochenhauer E.S., Cortet-Rudelli C., Cunnigham R.D., Conway-Myers B.A., Dewailly D., Azziz R. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab. 82:(2):1997 Feb;479-485.
72. Witchel S.F., Aston C.E. The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 13:(Suppl 5):2000;1315-1317.
73. Gilling-Smith C., Story H., Rogers V., Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 47:(1):1997 Jul;93-99.
74. Mifsud A., Ramirez S., Yong E.L. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab. 85:(9):2000 Sep;3484-3488.
75. Urbanek M., Legro R.S., Driscoll D.A., Azziz R., Ehrmann D.A., Norman R.J., et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 96:(15):1999 Jul 20;8573-8578.
76. Hickey T., Chandy A., Norman R.J. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab. 87:(1):2002 Jan;161-165.
77. Ibanez L., Ong K.K., Mongan N., Jaaskelainen J., Marcos M.V., Hughes I.A., et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab. 88:(7):2003 Jul;3333-3338.
78. Hogeveen K.N., Cousin P., Pugeat M., Dewailly D., Soudan B., Hammond G.L. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Invest. 109:(7):2002 Apr;973-981.
79. Moller D.E., Flier J.S. Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance). N Engl J Med. 319:(23):1988 Dec 8;1526-1529.
80. Talbot J.A., Bicknell E.J., Rajkhowa M., Krook A., O'Rahilly S., Clayton R.N. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 81:(5):1996 May;1979-1983.
81. Siegel S., Futterweit W., Davies T.F., Concepcion E.S., Greenberg D.A., Villanueva R., et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril. 78:(6):2002 Dec;1240-1243.
82. Tucci S., Futterweit W., Concepcion E.S., Greenberg D.A., Villanueva R., Davies T.F., et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab. 86:(1):2001 Jan;446-449.
83. Waterworth D.M., Bennett S.T., Gharani N., McCarthy M.I., Hague S., Batty S., et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet. 349:(9057):1997 Apr 5;986-990.
84. Ibanez L., Ong K., Potau N., Marcos M.V., de Zegher F., Dunger D. Insulin gene variable number of tandem repeat genotype and the low birth weight, precocious pubarche, and hyperinsulinism sequence. J Clin Endocrinol Metab. 86:(12):2001 Dec;5788-5793.
85. Burks D.J., White M.F. IRS proteins and beta-cell function. Diabetes. 50:(Suppl 1):2001 Feb;S140-S145.
86. Mkadem S.A., Lautier C., Macari F., Molinari N., Lefebvre P., Renard E., et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes. 50:(9):2001 Sep;2164-2168.
87. Dunaif A., Wu X., Lee A., Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab. 281:(2):2001 Aug;E392-E399.
88. Li M., Youngren J.F., Dunaif A., Goldfine I.D., Maddux B.A., Zhang B.B., et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab. 87:(9):2002 Sep;4088-4093.
89. Ehrmann D.A., Schwarz P.E., Hara M., Tang X., Horikawa Y., Imperial J., et al. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 87:(4):2002 Apr;1669-1673.
90. Escobar-Morreale H.F., Peral B., Villuendas G., Calvo R.M., Sancho J., San Millan J.L. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil Steril. 77:(3):2002 Mar;581-587.
91. Urbanek M., Du Y., Silander K., Collins F.S., Steppan C.M., Strauss J.F. 3rd, et al. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes. 52:(1):2003 Jan;214-217.
92. Elter K., Erel C.T., Cine N., Ozbek U., Hacihanefioglu B., Ertungealp E. Role of the mutations Trp8 => Arg and Ile15 => Thr of the human luteinizing hormone beta-subunit in women with polycystic ovary syndrome. Fertil Steril. 71:(3):1999 Mar;425-430.
93. Latronico A.C., Segaloff D.L. Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors. Am J Hum Genet. 65:(4):1999 Oct;949-958. Review.
94. Tong Y., Liao W.X., Roy A.C., Ng S.C. Association of AccI polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril. 74:(6):2000 Dec;1233-1236.
95. Conway G.S., Conway E., Walker C., Hoppner W., Gromoll J., Simoni M. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clin Endocrinol (Oxf). 51:(1):1999 Jul;97-99.
96. Urbanek M., Wu X., Vickery K.R., Kao L.C., Christenson L.K., Schneyer A., et al. Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab. 85:(12):2000 Dec;4455-4461.
97. Legro R.S., Muhleman D.R., Comings D.E., Lobo R.A., Kovacs B.W. A dopamine D3 receptor genotype is associated with hyperandrogenic chronic anovulation and resistant to ovulation induction with clomiphene citrate in female Hispanics. Fertil Steril. 63:(4):1995 Apr;779-784.
98. Kahsar-Miller M., Boots L.R., Azziz R. Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome. Fertil Steril. 71:(3): 1999 Mar;436-438.
99. Mandel F.P., Chang R.J., Dupont B., Pollack M.S., Levine L.S., New M.I., et al. HLA genotyping in family members and patients with familial polycystic ovarian disease. J Clin Endocrinol Metab. 56:(4):1983 Apr;862-864.
100. Hague W.M., Adams J., Algar V., Drummond V., Schwarz G., Bottazzo G.F., et al. HLA associations in patients with polycystic ovaries and in patients with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Clin Endocrinol (Oxf). 32:(4):1990 Apr;407-415.
101. Ober C., Weil S., Steck T., Billstrand C., Levrant S., Barnes R. Increased risk for polycystic ovary syndrome associated with human leukocyte antigen DQA1*0501. Am J Obstet Gynecol. 167:(6):1992 Dec;1803-1806.
102. Ibanez L., Potau N., Marcos M.V., de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in non obese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. 85:(9):2000 Sep;3251-3255.
103. Terouanne B., Paris F., Servant N., Georget V., Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol. 198:(1-2):2002 Dec 30;143-147.
104. Glueck C.J., Wang P., Fontaine R., Tracy T., Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health. 29:(3):2001 Sep;160-169.
105. Ibanez L., Valls C., Potau N., Marcos M.V., de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 85:(10):2000 Oct;3526-3530.
106. Mansfield R., Galea R., Brincat M., Hole D., Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 79:(4):2003 Apr;956-962.
107. Arslanian S.A., Lewy V., Danadian K., Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 87:(4):2002 Apr;1555-1559.
108. Ibanez L., Ong K., Ferrer A., Amin R., Dunger D., de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 88:(6):2003 Jun;2600-2606.
109. Ibanez L., Valls C., Ferrer A., Ong K., Dunger D.B., De Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab. 87:(6):2002 Jun;2870-2874.
110. Ibanez L., de Zegher F. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod. 18:(1):2003 Jan;57-60.
111. Jamieson E.M., Dean H. Metformin Use in Adolescent with PCOS-An Invited Editorial from the Pediatric Endocrinology Perspective. J Pediatr Adolesc Gynecol. 16:(2):2003 Apr;109-111.
112. Paradisi G., Steinberg H.O., Shepard M.K., Hook G., Baron A.D. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:(2):2003 Feb;576-580.
113. Veldhuis J.D., Zhang G., Garmey J.C. Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. J Clin Endocrinol Metab. 87:(3):2002 Mar;1129-1133.